Novozymes is trading at 57.19 as of the 1st of February 2025; that is 0.57 percent down since the beginning of the trading day. The stock's open price was 57.52. Novozymes has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 7th of May 2024 and ending today, the 1st of February 2025. Click here to learn more.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.. The company has 276.6 M outstanding shares. More on Novozymes AS
Novozymes AS [NVZMY] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novozymes's market, we take the total number of its shares issued and multiply it by Novozymes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novozymes AS classifies itself under Basic Materials sector and is part of Specialty Chemicals industry. The entity has 276.6 M outstanding shares.
Novozymes AS has accumulated about 1.01 B in cash with 4.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.67.
Check Novozymes Probability Of Bankruptcy
Our tools can tell you how much better you can do entering a position in Novozymes without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio File Import Now
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.